Genta withdraws Genasense NDA
Executive Summary
Genta is withdrawing its NDA for melanoma therapy Genasense, the company said May 13. The firm is requesting a meeting with FDA; co-developer Aventis plans to participate. FDA's Oncologic Drugs Advisory Committee voted 12 to 4 that Genta's pivotal trial for Genasense (oblimersen) did not show a "real effect" on progression-free survival (1"The Pink Sheet" May 10, 2004, p. 9)...
You may also be interested in...
Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.
Genta/Aventis Genasense appears to have a "real effect" on response rates in metastatic melanoma patients but not on progression-free survival or survival, FDA's Oncologic Drugs Advisory Committee concluded at its May 3 meeting
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.